Constant Contact Buys Bantam Live, Forest Pays $1.2B for Clinical Data, Paydiant Scores $7.6M, & More Boston-Area Deals News

Beacon Angels, Boston Harbor Angels, Maine Angels, North Country Angels, and Walnut Venture Associates, also participated in the deal.

—New York pharmaceutical company Forest Laboratories (NYSE: [[ticker:FRX]]) is paying $1.2 billion initially to acquire Newton, MA-based drugmaker Clinical Data (NASDAQ: [[ticker:CLDA]]), which last month nabbed FDA approval for its anti-depression drug, vilazodone. The $30 per share payment represents a 6.6 percent premium above Clinical Data’s average stock price since its drug was approved on January 24th. And Forest could pay another $6 per share to Clinical Data stockholders if vilazodone hits certain sales goals over the next seven years.

—Paydiant, a Boston-area stealthy startup working on mobile payments technology, collected $7.6 million in a Series A deal led by North Bridge Venture Partners and General Catalyst Partners.

—Boston-based Acetylon Pharmaceuticals, a developer of drugs for treating cancer and autoimmune diseases, brought in $12.4 million of an equity-based funding round that could hit $30 million, an SEC filing showed.

Pages: Page 1, Page 2

Author: Erin Kutz

Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.